GeneHealth - Your precision medicine

Wolman Disease

Disease Details

Family Health Simplified

Buy Membership

Description: Wolman disease is a rare genetic disorder characterized by the deficiency of the enzyme lysosomal acid lipase, leading to the accumulation of lipids in various body tissues.
Type: Wolman disease is an autosomal recessive genetic disorder.
Signs And Symptoms: Wolman disease is a rare, inherited lipid storage disorder caused by the deficiency of the enzyme lysosomal acid lipase. Signs and symptoms of Wolman disease typically present in infancy and may include:

- Failure to thrive and poor weight gain
- Severe liver enlargement (hepatomegaly) and spleen enlargement (splenomegaly)
- Gastrointestinal issues such as vomiting, diarrhea, and fatty stools (steatorrhea)
- Calcification of the adrenal glands, visible on X-rays
- Jaundice
- Developmental delays
- Progressive weakness and muscle wasting

The disease often leads to severe complications and is typically fatal within the first year of life.
Prognosis: Infants with LAL deficiencies typically show signs of disease in the first weeks of life and if untreated, die within 6–12 months due to multi-organ failure. Older children or adults with LAL-D may remain undiagnosed or be misdiagnosed until they die early from a heart attack or stroke or die suddenly of liver failure. The first enzyme replacement therapy was approved in 2015. In those clinical trials nine infants were followed for one year; 6 of them lived beyond one year. Older children and adults were followed for 36 weeks.
Onset: The onset of Wolman disease typically occurs in infancy, usually within the first few weeks to months of life.
Prevalence: Wolman disease is an extremely rare inherited disorder. Its prevalence is estimated to be less than 1 in 500,000 live births.
Epidemiology: Depending on ethnicity and geography, prevalence has been estimated to be between 1 in 40,000 and 1 in 300,000; based on these estimates the disease may be underdiagnosed. Jewish infants of Iraqi or Iranian origin appear to be most at risk based on a study of a community in Los Angeles in which there was a prevalence of 1 in 4200.
Intractability: Wolman disease is generally considered intractable due to its severe and progressive nature. It is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme lysosomal acid lipase (LAL). The disease typically leads to rapid deterioration in infancy, and without treatment, it often results in early death. While enzyme replacement therapy (ERT) has shown some promise, it may not be universally effective for all patients, thus making the disease challenging to manage.
Disease Severity: Wolman disease is a rare and severe hereditary lysosomal storage disorder. It generally presents in infancy and leads to early death if untreated.
Healthcare Professionals: Disease Ontology ID - DOID:14497
Pathophysiology: Wolman disease is a rare genetic disorder caused by a deficiency in the lysosomal enzyme acid lipase. This enzyme deficiency leads to the accumulation of cholesteryl esters and triglycerides in various tissues. The primary sites of accumulation include the liver, spleen, adrenal glands, and intestines. This build-up results in widespread organ damage and dysfunction, severe hepatosplenomegaly, adrenal calcification, and malabsorption in the intestines. The disease typically presents in infancy and is characterized by rapid progression, often leading to severe complications and early mortality if left untreated.
Carrier Status: Wolman disease is an autosomal recessive disorder. Carrier status means that an individual has one mutated copy of the gene associated with the disease (LIPA gene) and one normal copy. Carriers typically do not show symptoms of the disease but can pass the mutated gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two mutated copies and have Wolman disease.
Mechanism: Wolman disease is a rare lysosomal storage disorder caused by mutations in the LIPA gene, which encodes the enzyme lysosomal acid lipase (LAL). The deficiency of LAL enzyme activity leads to the intracellular accumulation of cholesteryl esters and triglycerides in various tissues, including the liver, spleen, adrenal glands, and intestines.

**Molecular Mechanisms:**

1. **LIPA Gene Mutation**: Mutations in the LIPA gene result in reduced or absent activity of the LAL enzyme. Over 40 different mutations, including missense, nonsense, and splice-site mutations, have been identified in patients with Wolman disease.

2. **Lipid Accumulation**: The lack of functional LAL enzyme impairs the breakdown of cholesteryl esters and triglycerides within lysosomes. Consequently, these lipids accumulate within the cells, leading to cell and tissue dysfunction.

3. **Cellular Damage and Inflammation**: Accumulated lipids in macrophages and other cells cause them to become foam cells, contributing to widespread tissue inflammation and damage. This is particularly detrimental in the liver, spleen, and adrenal glands, where it can lead to hepatomegaly, splenomegaly, and calcification of the adrenal glands.

4. **Organ Dysfunction**: The extensive storage of lipids impairs the normal function of affected organs. In the liver, it can lead to hepatic fibrosis and cirrhosis. In the intestines, it can cause malabsorption and gastrointestinal symptoms.

5. **Systemic Manifestations**: The systemic nature of lipid storage leads to multiple clinical manifestations, including failure to thrive in infancy, vomiting, diarrhea, anemia, and developmental delays.

Early diagnosis and treatment options, such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), may help manage some of the symptoms and improve the quality of life for patients with Wolman disease.
Treatment: Wolman disease is a rare genetic disorder caused by a deficiency of the enzyme acid lipase. Treatment options include enzyme replacement therapy, specifically sebelipase alfa, which can help manage symptoms and improve outcomes. Hematopoietic stem cell transplantation has also been explored in some cases. Supportive care is crucial in managing complications and maintaining quality of life. New therapies and approaches are under continuous study to improve treatment outcomes.
Compassionate Use Treatment: Wolman disease is a rare, inherited disorder characterized by the deficiency of the enzyme lysosomal acid lipase (LAL). Compassionate use and experimental treatments for Wolman disease may include:

1. **Sebelipase Alfa (Kanuma)**: This enzyme replacement therapy is approved and can also be provided under compassionate use for patients lacking access through standard treatment programs or who meet specific criteria set by regulatory authorities.

2. **Gene Therapy**: While still mainly in experimental stages, gene therapy aims to correct the underlying genetic defect causing Wolman disease. Clinical trials are ongoing to test its safety and efficacy.

Patients seeking compassionate use treatments should consult with their healthcare providers to understand the eligibility, potential benefits, and risks.
Lifestyle Recommendations: For individuals diagnosed with Wolman disease, lifestyle recommendations primarily focus on supportive care and symptom management due to the progressive and severe nature of the condition. Specific recommendations may include:

1. **Nutritional Support**: Since Wolman disease often results in malabsorption and gastrointestinal complications, affected individuals may require specialized dietary plans. This may include high-calorie diets, fat-soluble vitamin supplements, and sometimes parenteral nutrition.

2. **Regular Medical Follow-up**: Frequent consultations with a multidisciplinary medical team, including gastroenterologists, hepatologists, and dietitians, are crucial for monitoring disease progression and managing symptoms effectively.

3. **Medication Adherence**: Enzyme replacement therapy (ERT) with sebelipase alfa is available and should be administered as prescribed to help manage the condition.

4. **Infection Prevention**: Due to potential complications such as liver or spleen enlargement, it is important to avoid infections. Preventive measures, including vaccinations and hygiene practices, are essential.

5. **Physical Activity**: While strenuous activities may be limited due to health complications, regular, gentle physical activity can help maintain general health and well-being.

6. **Psychosocial Support**: Emotional and psychological support for both the patient and their family is important, given the chronic and serious nature of the disease. Support groups and counseling may be beneficial.

7. **Emergency Preparedness**: Families should have a plan in place for potential emergencies, including having medical information readily accessible and knowing when and where to seek urgent medical care.

These recommendations aim to improve quality of life and manage symptoms but do not cure the disease. Regular communication with healthcare providers is essential for optimizing care and adjusting lifestyle modifications as needed.
Medication: Wolman disease is a rare genetic disorder that affects lipid metabolism. Currently, the most specific treatment approved is sebelipase alfa, an enzyme replacement therapy. It helps to replace the deficient lysosomal acid lipase enzyme in affected individuals. Otherwise, treatment primarily focuses on managing symptoms and supportive care.
Repurposable Drugs: Wolman disease, also known as lysosomal acid lipase deficiency, is a rare genetic disorder. There are no widely recognized repurposable drugs yet specifically for Wolman disease. Current treatment options focus mainly on enzyme replacement therapy (ERT) with sebelipase alfa, which is the approved treatment. Some researchers are investigating other therapeutic approaches such as gene therapy, but these are still in experimental stages.
Metabolites: Wolman disease is characterized by the accumulation of certain metabolites due to a deficiency in the enzyme lysosomal acid lipase (LAL). The primary metabolites that accumulate include cholesterol esters and triglycerides, which build up in various tissues such as the liver, spleen, and adrenal glands.
Nutraceuticals: Wolman disease is a rare genetic disorder caused by a deficiency of the enzyme lysosomal acid lipase. There are no specific nutraceuticals proven to treat or manage Wolman disease effectively. The primary treatment approaches typically involve enzyme replacement therapy and supportive care to manage symptoms. Nutritional and dietary adjustments might be necessary under the guidance of healthcare professionals to address malabsorption and other related issues.
Peptides: Wolman disease is a rare genetic disorder characterized by the deficiency of the lysosomal acid lipase enzyme, resulting in the accumulation of lipids in various tissues. Peptide-based treatments are not commonly associated with Wolman disease. Current therapeutic approaches primarily focus on enzyme replacement therapy (ERT) with recombinant human lysosomal acid lipase (e.g., sebelipase alfa). Nanotechnology-based solutions are still under exploration and are not yet standard treatment options for Wolman disease.